Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MorphoSys AG
Leading the group were Trinomab Biotech, which develops antibodies for infectious diseases, and cell and gene developers BRL Medicine and XellSmart.
Monjuvi is still struggling to make progress commercially and the hopes of lucrative royalty streams from partners Roche and GSK have dried up but MorphoSys is keeping faith in its fully owned pipeline.
Human Immunology Biosciences (HI-Bio) launched with $120m and two candidates from MorphoSys, including the CD38 inhibitor felzartamab already in the clinic for immune-mediated kidney diseases.
SIGA provides an update on its monkeypox program, while Massive Bio announces progress on its AI platform for connecting cancer patients to trials, with additional updates from BridgeBio, the Oncology Institute, and CROs Caidya, Charles River Labs, Syneos Health and PPD parent Thermo Fisher Scientific.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Lanthio Pharma B.V.
- MorphoSys US Inc.
- Sloning BioTechnology
- Constellation Pharmaceuticals, Inc.